ABVC BioPharma's Affiliate OncoX Acquires Lycopenoid Platform in $4.06 Million Deal
TL;DR
ABVC BioPharma's licensing deal with OncoX could yield up to $105 million, showcasing a strategic move to capitalize on the booming oncology market.
ABVC's affiliate OncoX acquires Lycogen® platform for $4.06 million, aiming to develop oncology treatments with a projected $25-30 million revenue over five years.
The acquisition of Lycogen® by OncoX, under ABVC's strategy, promises advancements in oncology treatments, potentially improving patient outcomes worldwide.
Lycogen®, a next-gen lycopene-analog, joins OncoX's pipeline, highlighting ABVC's innovative approach to leveraging natural compounds for cancer therapy.
Found this article helpful?
Share it with your network and spread the knowledge!
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced that its affiliate, OncoX BioPharma Inc., has acquired the Lycopenoid Lycogen® platform in a deal valued at approximately $4.06 million. This acquisition includes patented manufacturing technology and commercialization rights, previously held by Asia-Pacific Biotech Developing Inc. (APBDI). The Lycogen® platform, known for its next-generation lycopene-analog produced by microbial fermentation, has shown preclinical promise in cancer-related and metabolic disease models due to its potent antioxidant and anti-inflammatory properties.
The strategic acquisition is expected to unlock commercial potential across dermatology, oncology, and nutraceutical sectors, with OncoX forecasting cumulative revenues of $25–30 million over the next five years. ABVC stands to benefit from this growth through royalty payments, exemplifying its strategy of leveraging affiliate-driven development for non-dilutive revenue growth. This move not only strengthens OncoX's pipeline of natural compound-based therapies but also highlights ABVC's capability to monetize platform assets through strategic partnerships.
ABVC's licensing agreement with OncoX, valued up to $105 million, has already seen $25 million in equity-based consideration, showcasing the viability of ABVC's revenue model. With the global oncology drug market projected to grow to $484 billion by 2032 and the lycopene-based ingredients market expected to surpass $170 million by 2029, this transaction positions ABVC and OncoX to capitalize on the increasing demand for multifunctional natural compounds in therapeutic and consumer applications.
Curated from NewMediaWire
